Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Publication · Regulating human participants research

Regulatory Measures for Research Involving Human Participants: Ethical Declarations, Guidance, Legislation and Journal Policy

The framework governing research with human participants comprises four categories of instrument with different degrees of force: ethical declarations that are not law, international guidance that is not binding, national legislation that is binding, and journal policy that determines publication. Confusion between these categories is the most common error in ethics statements and is readily identified by editors.

Pubrica AcademyWritten by the medical writing and biostatistics teams Reviewed byPubrica biostatistics team Published9 October 2026 Last checked9 October 2026 Reading time13 minutes Sources30 peer-reviewed

Research teams asked which rules apply to their study commonly cite the Declaration of Helsinki and their ethics committee. Both answers are correct, but neither is sufficient. The Declaration of Helsinki is not in itself law in any jurisdiction; ethics committees apply national regulations that differ between countries; data protection law applies in addition to both and addresses a different question; and the ICMJE Recommendations, which are not law in any sense, determine whether a journal will publish the work. This article distinguishes the four layers and describes what each requires authors to document.

Learning objectives

  • The instruments in this framework that constitute binding law and those that do not, and the implications of this distinction for the ethics statement
  • The obligations of the Declaration of Helsinki as revised in October 2024, beyond citation of the declaration itself
  • The matters an ethics committee assesses, and the expectations of the WHO standards for the committee
  • The reasons informed consent frequently fails to achieve comprehension even when documentation is complete
  • The reasons registration and complete reporting are regarded as ethical obligations rather than administrative ones
  • The preparation of an ethics statement that will not attract editorial queries

Common misconceptions

  • “The Declaration of Helsinki is international law.” It is a declaration of the World Medical Association that carries considerable moral and professional weight and is incorporated into many national regulations and journal policies; it is not, however, itself legislation, and it imposes no sanction of its own.
  • “Ethics approval resolves questions of data protection.” It does not. An ethics committee determines whether the research is acceptable, whereas data protection law concerns the legal basis on which data are processed, and the GDPR (General Data Protection Regulation) provides six such bases, of which consent is only one.
  • “Registration of the trial at the time of manuscript submission is sufficient.” The ICMJE requires registration in a public registry at or before the time of first patient enrolment. Retrospective registration does not satisfy the policy, and by the time of manuscript preparation the deadline has already passed.
  • “A signed consent form indicates that the participant understood.” Tam and colleagues, in the Bulletin of the World Health Organization, reviewed participants’ understanding of informed consent across three decades of trials and found that comprehension of key elements was frequently poor, particularly with respect to randomisation and the right to withdraw.
  • “Failure to publish a completed study is merely a missed opportunity.” Antes and Chalmers argued in the Lancet that under-reporting of clinical trials is unethical, because participants accepted risk on the understanding that the knowledge would be produced.

Four categories of instrument and their legal force

The documents that govern research with human participants are customarily listed together, which obscures the fact that they operate in fundamentally different ways. The distinction is substantive: it determines which body can impose sanctions, to which body an appeal can be made, and what a reviewer is entitled to require.

Ethical declarations state principles. The WMA Declaration of Helsinki, revised in October 2024, sets out ethical principles for medical research involving human participants and is the central example; its 2013 revision was published in JAMA, and the Belmont Report performs a similar founding role in the United States 24,30. These instruments carry substantial professional weight and are frequently incorporated by reference into national law and journal requirements, but they are not legislation and impose no penalty directly.

International guidance translates principles into operational expectations. The Council for International Organizations of Medical Sciences issued the fourth edition of its International Ethical Guidelines for Health-related Research Involving Humans in 2016, and the World Health Organization’s Standards and Operational Guidance for Ethics Review sets out what a review committee should itself be capable of 4,18. Neither is binding on investigators; both form the basis on which a well-functioning committee operates.

National and supranational legislation is binding and varies between jurisdictions. This layer contains the substantive legal obligations and sanctions, and it is the layer most often omitted from a methods section. The GDPR is the most prominent European example, but clinical trial legislation, human tissue legislation and professional regulation also belong to this layer.

Journal and publisher policy is not law but determines whether a study is published. The ICMJE Recommendations and COPE’s Core Practices are the most influential, and compliance with them is checked at submission in a way that does not apply to any other instrument in this list 1,5.

The instruments and the consequences each can impose

InstrumentWhat it isBinding?What it means in practice
Declaration of Helsinki
World Medical Association, revised October 2024
A declaration of medical ethics for research on human participantsNo, in itselfIncorporated by reference into many national regulations and into ICMJE policy; the clause cited in the methods statement
Belmont Report
US National Commission
The founding statement of respect for persons, beneficence and justiceNo, in itselfThe conceptual basis of US human-subjects regulation and of IRB reasoning generally
CIOMS guidelines
4th edition, 2016
Operational international ethical guidanceNoThe principal instrument for vulnerability, low-resource settings and post-trial obligations; the basis of a well-functioning committee’s reasoning
WHO Standards and Operational GuidanceStandards for how ethics review itself should be conductedNoApplies to the committee as much as to the investigator; relevant where a committee’s process is inadequate
GDPR and national implementing lawData-protection legislation, directly applicable with Member State derogationsYesSubstantive legal obligations and sanctions; determines the legal basis for processing, which ethics approval does not
ICMJE RecommendationsEditorial policy on conduct, reporting and publicationNo, but decisiveChecked at submission: Helsinki conformity, ethics approval stated in Methods, prospective registration, authorship criteria
COPE Core PracticesStandards for editorial handling of integrity problemsNoThe framework an editor will use if a consent, authorship or misconduct question arises after publication

Characterisation of each instrument from the documents themselves. “Binding” refers to legal force in its own right; several non-binding instruments acquire force through incorporation into national law, funder conditions or journal policy. National implementations of the data-protection row differ, and investigators should confirm their position with their institution.

Obligations under the Declaration of Helsinki

“Conducted in accordance with the Declaration of Helsinki” appears in thousands of methods sections, many written by authors who have not consulted the document recently. Its commitments are more specific than the phrase suggests, and several of them can be verified by a reviewer.

The Declaration requires that research involving human participants be preceded by a protocol submitted to an independent research ethics committee before the study begins, and that the protocol describe the funding, the sponsors, institutional affiliations, conflicts of interest and incentives, and the provisions for treating or compensating participants harmed by taking part 24. It requires that the wellbeing of the individual participant takes precedence over all other interests. It requires that research be registered in a publicly accessible database before recruitment of the first participant, and that researchers have a duty to make the results publicly available, including negative and inconclusive results 24. It requires that participants be properly informed of the aims, methods, funding, conflicts, anticipated benefits, risks and discomforts, and of their right to refuse or withdraw without reprisal.

Two of these requirements merit attention because authors often treat them as administrative. Prospective registration and the duty to report results are both located within the ethical framework, not in a publisher’s list of preferences. Antes and Chalmers made this point in the Lancet when they argued that under-reporting of clinical trials is unethical, and it explains why Steinbrook, writing in the New England Journal of Medicine on public registration of trials, treated registration as a matter of accountability to participants rather than of record-keeping 26,27.

Scope of ethics committee review

An ethics committee does not audit the writing or the statistics for their own sake. It determines whether it is acceptable to expose these participants to this risk for this prospective knowledge, and the elements it weighs are broadly consistent across jurisdictions: scientific validity, because an invalid study cannot produce the benefit that justifies the risk; the risk–benefit balance; equitable selection of participants; the adequacy of the consent process and documents; special protections where participants may be vulnerable; privacy and confidentiality arrangements; the competence of the investigators and the suitability of the site; and the provisions for harm.

The World Health Organization’s Standards and Operational Guidance for Ethics Review of Health-Related Research with Human Participants sets expectations on the committee as well as the applicant: documented procedures, a membership that includes non-scientific and lay members, declared conflicts among reviewers, written decisions with reasons, and arrangements for ongoing review rather than a single gate at the start 4. A committee that does not operate in this way is itself deficient, and some journals and funders will take note.

Scientific validity is the element authors most often underestimate. Under this framework, a study that cannot answer its question is not merely weak but unethical, because participants bear risk without any prospect of benefit. It is also the point at which the ethics committee and the journal reviewer address the same question from different perspectives, which is a strong reason to finalise the design and the analysis plan in advance. The pages on the clinical study protocol and on biostatistics address the parts of a submission that most frequently attract queries.

Informed consent must achieve several objectives simultaneously. It must disclose the purpose, procedures, risks, expected benefits, alternatives, funding and conflicts; it must make clear that participation is voluntary and that refusal or withdrawal carries no penalty and no effect on care; it must be obtained before any study procedure; it must be documented; and it must be given by someone with the capacity to give it, or by an authorised representative with assent from the participant where that is possible.

The evidence indicates that documentation succeeds far more reliably than comprehension. Tam and colleagues, in the Bulletin of the World Health Organization, conducted a systematic review and meta-analysis of participants’ understanding of informed consent in clinical trials spanning three decades, and found that comprehension of several key elements remained poor across that period — with randomisation, the distinction between research and care, and the right to withdraw among the least well understood 2. The implication is not that consent is futile but that signature rates are an inappropriate measure of it. Where a study involves any complexity, the consent process should include an assessment of understanding rather than solely a check of documentation.

Two further practical points apply. First, consent is a process rather than a single event: material changes to the protocol, new safety information or a long study duration may each require re-consent. Second, the consent document is where research ethics and data-protection law must coexist without being conflated, a topic addressed in detail in the data-protection obligations across trial stages. Our page on the informed consent form covers the document itself.

Vulnerability and the role of the CIOMS guidelines

The Declaration of Helsinki states the principle that groups who are under-represented in research should be given appropriate access to participation, and that groups who are vulnerable should receive specifically considered protection 24. It provides little guidance on implementation. The CIOMS International Ethical Guidelines, in their fourth edition issued in 2016, contain the operational detail, and they are the appropriate instrument when a study involves children, people lacking capacity, pregnant participants, prisoners, or research conducted in low-resource settings where the standard of available care differs from that of the sponsor’s country 18.

The CIOMS guidelines are also notable for reframing vulnerability away from a list of categories and towards an analysis of specific features that make particular participants susceptible to harm or to inadequate consent in a particular study 18. This approach is more demanding than a categorical checklist, and it is the approach a well-informed committee will expect. For multinational research, the guidelines also address the obligations of sponsors towards host communities, including the availability of effective interventions after the trial ends — an issue that a protocol should address explicitly rather than leave to goodwill.

Registration and reporting as ethical obligations

The ICMJE requires clinical trials to be registered in a public registry at or before the time of first patient enrolment, and retrospective registration at the point of submission does not satisfy the policy 1. The deadline is absolute: once a manuscript exists, a missed registration cannot be corrected, and journals do decline manuscripts on this ground.

The requirement does not exist for administrative convenience. Easterbrook and colleagues, in the Lancet, documented publication bias in clinical research, and Stern and Simes, in the BMJ, showed in a cohort of clinical research papers that publication was systematically delayed for studies without statistically significant results 28,29. A literature assembled from the subset of studies that produced favourable findings misleads every clinician who relies on it, and the participants in unpublished studies accepted risk to generate knowledge that was subsequently withheld. This underlies Antes and Chalmers’ argument in the Lancet that under-reporting is an ethical failure rather than a bibliographic one, and Steinbrook’s account in the New England Journal of Medicine of why public registration became a condition of publication.

In practice, two dates should be recorded before recruitment: the ethics approval date and the registration date, in that order, both preceding the enrolment of the first participant. Pubrica’s reporting guidelines hub covers the CONSORT, STROBE and PRISMA items that subsequently govern the completeness of reporting.

Scope and limits of data protection law

Data-protection law addresses a different question from research ethics, and the fact that both involve a concept termed consent is a coincidence of terminology that causes persistent confusion. An ethics committee asks whether it is acceptable to enrol a given person. Data-protection law asks on what legal ground the organisation is processing that person’s information, and whether the person has been informed.

Christofidou and colleagues, in Frontiers in Medicine, state the structural point clearly: the GDPR provides six legal bases for processing, and consent is only one of them. European guidance has moved away from consent as the basis for research. The European Commission issued eleven questions and answers on the interplay between the Clinical Trials Regulation and the GDPR and concluded that consent will not be the appropriate legal basis in most cases, and the European Data Protection Board addressed the same interplay in its Opinion 3/2019, issued in 2019 12. Gefenas and colleagues, in Medicine, Health Care and Philosophy, describe the resulting situation as informed consent standing at a cross-road between two regimes that use the word differently 7.

The implications for investigators are specific. Ethics approval does not establish a legal basis, and neither does a participant’s signature on a consent form. The determination is made by the institution that holds the data, acting as controller, and the applicable national implementing law differs between countries. Investigators should obtain the data protection officer’s determination in writing, retain it, and avoid any methods sentence implying that the ethics committee resolved the question.

Writing a verifiable ethics statement

Nearly all of this framework reaches the reader through one short passage in the Methods, and most versions of that passage are too brief to be verifiable. The ICMJE requires that research conform to the Declaration of Helsinki, most recently revised in October 2024, and that approval by an independent ethics committee or institutional review board be stated in the Methods section 1. A statement that satisfies this requirement names the committee, gives its reference, specifies the type of consent obtained and from whom, and, where applicable, gives the registration identifier and the dates that demonstrate that registration was prospective.

2024the year of the current revision of the Declaration of Helsinki
Methodsthe section where ethics committee or IRB approval must be stated
First enrolmentthe deadline for public trial registration — at or before, never retrospectively

Three requirements stated in the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals.

The ethics and consent statement in a Methods section

Unverifiable

Ethical approval was obtained for this study and all patients provided informed consent. The study was conducted in accordance with accepted ethical standards.

Which committee? The committee is neither named nor referenced, so no reader or editor can verify that review took place.

Which ethical standards? “Accepted” names nothing. The ICMJE requires conformity with the Declaration of Helsinki, and the revision relied on should be stated as such; the current revision dates from October 2024.

What kind of consent, from whom? Whether consent was written or verbal, obtained from the participant or a representative, and obtained before or after study procedures is not stated.

Was the trial registered, and when? Not reported. The ICMJE deadline is at or before first enrolment, so the dates are essential.

Who is the data controller? Not reported, and the sentence implies that ethics approval resolved the data-protection question, which it does not.

Checkable line by line

The study was approved by the Institutional Ethics Committee of the coordinating centre (reference IEC/2024/0147) and, at each participating site, by the local committee listed in Supplementary Table 1. The study was conducted in accordance with the Declaration of Helsinki as revised in 2013. Written informed consent was obtained from every participant before any study procedure; where a participant lacked capacity to consent, written consent was obtained from a legally authorised representative and assent was sought from the participant. The trial was registered in a public registry before enrolment of the first participant (registration CTRI/2024/03/064321, registered 14 March 2024; first enrolment 2 April 2024). The coordinating institution is the data controller for the study, and the legal basis for processing and the applicable national implementing law were confirmed by its data protection officer.

The committee is named with a reference number, and multi-site approvals are accounted for rather than implied.

The Helsinki revision is specified, which is what the ICMJE requires.

Consent is characterised: written, prospective, and with the route for participants lacking capacity set out including assent.

Registration is reported with both dates, so that readers can verify that it was prospective.

The controller and legal basis are distinguished from the ethics approval and attributed to the person who determined them.

The second version is four sentences longer and converts five unverifiable assertions into five verifiable facts. Each addition corresponds to a requirement of a specific body: the committee reference to the institution, the Helsinki revision and the registration dates to the ICMJE, the consent detail to the Declaration itself, and the controller sentence to data-protection law. The final sentence makes no claim about which legal basis applies; it states who determined it, which is the only accurate statement an author can make.

Jurisdictional variation and unresolved questions

Three caveats apply to any account of this kind.

National implementation differs, including inside the EU. The GDPR expressly permits Member States to add conditions for health and genetic data and to legislate research derogations, and they have done so unevenly, so a multinational study can face different requirements at each site for one protocol 19. Crowhurst and colleagues, in Nurse Researcher, examine this question for retrospective reviews of patients’ records and necessarily reach a country-specific answer 11. Outside Europe the regulatory architecture differs more fundamentally again, while the ICMJE requirements do not change at all.

Whether certain activities constitute research is genuinely contested. Service evaluation, audit, retrospective record review and single-patient case reports occupy a grey zone that institutions handle differently, and no European instrument resolves it. Investigators should obtain their institution’s determination in writing and cite it; the page on consent and data protection in a case report addresses the most difficult form of this problem.

Commentators disagree about the extent to which the law obstructs research. Casali’s European Society for Medical Oncology position paper in Annals of Oncology warned of substantial risk to clinical research from the data protection regime, while Rumbold and Pierscionek, in the Journal of Medical Internet Research, and Chassang, in ecancermedicalscience, reached more measured conclusions 15,16,23. Patient opinion complicates it further: Richter and colleagues, in the European Journal of Human Genetics, found more acceptance of research use of clinical data without consent than the regulatory debate implies 13. None of this is resolved. Investigators should therefore confirm their position with their own data protection officer and ethics committee rather than rely on any general account, including this one, which describes requirements and does not constitute legal advice.

Key points

Key points

Research with human participants is governed by four layers, of which only one is law. Ethical declarations such as the WMA Declaration of Helsinki, revised in October 2024, state the principles; international guidance such as the fourth edition of the CIOMS (Council for International Organizations of Medical Sciences) guidelines of 2016 and the WHO ethics review standards make them operational; national and supranational legislation is binding and varies between jurisdictions; and journal policy, chiefly the ICMJE Recommendations and COPE’s Core Practices, determines publication. Two deadlines within this framework cannot be met retrospectively: ethics approval before the study begins, and public registration at or before first enrolment. Ethics approval does not establish a legal basis for processing data; that determination rests with the institution as data controller, under national law that varies.

Application to your study

Application to your study

  1. List the instruments that apply to the study, distinguishing binding instruments from influential ones, and name the national legislation rather than referring to “applicable regulations”.
  2. Consult the Declaration of Helsinki before citing it. The protocol should be checked specifically for disclosure of funding and conflicts of interest, provision for harm, prospective registration and the duty to report results.
  3. Register the trial before the first participant is enrolled, and record both dates. This deadline cannot be remedied once it has passed.
  4. Incorporate an assessment of comprehension into the consent process in addition to a signature line, particularly for randomisation and the right to withdraw, which the review evidence indicates are least well understood.
  5. Use the CIOMS guidelines rather than the Declaration of Helsinki for vulnerability, and provide a specific analysis of the factors that make the participants susceptible rather than naming a category.
  6. Request written confirmation of the legal basis from the data protection officer, together with the national implementing law that applies at each site, and file the reply with the protocol.
  7. Revise the ethics statement so that it can be verified: it should state the named committee and reference, the revision of the Declaration of Helsinki relied on (the current revision dates from October 2024), the form of consent and who provided it, and the registration identifier with its date.
  8. Plan publication of the results, including null results, at the outset, because the duty to report forms part of the ethical framework rather than an adjunct to it.

Frequently asked questions

Not in itself. It is a declaration of the World Medical Association and creates no sanction of its own. Its force derives from incorporation: many national regulations and professional codes adopt it by reference, funders require conformity, and the ICMJE requires that research conform to the Declaration, most recently revised in October 2024, and that the statement appear in the Methods. In practice, a breach will rarely incur a legal penalty directly, but it will reliably prevent publication and may damage institutional standing. It should be treated as the substantive standard that both the committee and the journal apply, and the revision year should be cited rather than the Declaration generically.

No, and this is the most common confusion in this area. The two bodies of rules address different questions. An ethics committee decides whether it is acceptable to involve these participants in this research. Data-protection law asks on what legal ground the organisation processes their personal data, and the GDPR provides six such grounds, of which consent is only one; the European Commission’s eleven questions and answers on the Clinical Trials Regulation concluded that consent will not usually be appropriate. The determination belongs to the institution acting as controller, under national implementing law that differs between countries. It should be obtained in writing from the data protection officer and kept with the protocol.

The ICMJE requires registration in a public registry at or before the time of first patient enrolment, and registering retrospectively at the point of submission does not satisfy the policy. The Declaration of Helsinki states the same obligation in ethical terms, requiring registration in a publicly accessible database before recruitment of the first participant. The deadline cannot be remedied: a manuscript cannot correct a missed registration, and journals decline manuscripts on this ground. The registration date and the first enrolment date should be recorded together so that the prospective relationship is demonstrated in the methods section rather than asserted.

Less well than consent rates suggest. Tam and colleagues, in the Bulletin of the World Health Organization, systematically reviewed and meta-analysed studies of participants’ understanding of informed consent in clinical trials across three decades and found comprehension of several key elements persistently poor, with randomisation, the distinction between research participation and clinical care, and the right to withdraw among the least well understood. The implication for practice is to assess understanding rather than documentation: a brief teach-back on those three points, recorded in the file, addresses the elements the evidence identifies as weakest. A signature establishes that the process took place, not that it was effective.

Scientific validity is assessed first, because a study that cannot answer its question exposes participants to risk for no prospective benefit, which the framework treats as unethical rather than merely weak. Then the risk–benefit balance, equitable selection of participants, the adequacy of the consent process and documents, protections where participants may be vulnerable, privacy and confidentiality arrangements, investigator competence and site suitability, and provision for participants harmed by taking part. The WHO Standards and Operational Guidance also set expectations on the committee itself: documented procedures, lay and non-scientific members, declared reviewer conflicts, written reasons, and ongoing rather than one-off review.

The CIOMS International Ethical Guidelines, fourth edition, issued in 2016. The Declaration of Helsinki states the principle — specific protection for vulnerable groups and appropriate access to participation for under-represented ones — but CIOMS supplies the operational detail for children, people lacking capacity, pregnant participants, prisoners and research in low-resource settings, and it addresses sponsors’ obligations to host communities including post-trial access. CIOMS also reframes vulnerability away from a list of categories and towards an analysis of the specific features that make particular participants susceptible in a particular study, which is what a well-briefed committee will expect to see.

It depends on the jurisdiction, and this is a genuine grey zone rather than a settled matter. Institutions and national frameworks differ on whether service evaluation, clinical audit, retrospective record review and single-patient case reports count as research requiring committee review, and no European instrument resolves it. Crowhurst and colleagues, in Nurse Researcher, examine retrospective reviews of patients’ data and reach a necessarily country-specific conclusion. The reliable approach is to obtain the institution’s determination in writing before the study begins, and to state it in the Methods, including where review was not required and who made that decision.

Under this framework, yes. Antes and Chalmers argued in the Lancet that under-reporting of clinical trials is unethical, because participants accepted risk on the understanding that knowledge would result, and because a literature assembled from the findings that happened to be favourable misleads clinicians. The empirical basis is robust: Easterbrook and colleagues documented publication bias in the Lancet, and Stern and Simes showed in the BMJ that publication was systematically delayed for studies without statistically significant results. The Declaration of Helsinki states the duty to make results publicly available, including negative and inconclusive findings, which puts it inside the ethical obligations rather than alongside them.

References

  1. International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. ICMJE. 2026. read 9 October 2026. icmje.org
  2. Tam NT, Huy NT, Thoa TB, Long NP, Trang NT, Hirayama K, et al. Participants' understanding of informed consent in clinical trials over three decades: systematic review and meta-analysis. Bulletin of the World Health Organization. 2015;93:186-198H. doi:10.2471/BLT.14.141390 read 9 October 2026. doi.org/10.2471/BLT.14.141390
  3. International Committee of Medical Journal Editors. The New ICMJE Recommendations (August 2013). ICMJE. 2013. read 9 October 2026. icmje.org
  4. World Health Organization. Standards and Operational Guidance for Ethics Review of Health-Related Research with Human Participants. WHO. 2011. read 9 October 2026. equator-network.org
  5. Committee on Publication Ethics. Core Practices. COPE. read 9 October 2026. equator-network.org
  6. Christofidou M, Arvanitis TN, Kalra D, Lea N, Shabani M, Coorevits P. Data altruism and the 'consent' question: a study into the 'consent' models used under the GDPR and how the data altruism mechanism can act as a potential solution for the research community in the reuse of health data. Frontiers in Medicine. 2025;11:1489925. doi:10.3389/fmed.2024.1489925 read 9 October 2026. doi.org/10.3389/fmed.2024.1489925
  7. Gefenas E, Lekstutiene J, Lukaseviciene V, Hartlev M, Mourby M, Cathaoir KO. Controversies between regulations of research ethics and protection of personal data: informed consent at a cross-road. Medicine, Health Care and Philosophy. 2022;25:23-30. doi:10.1007/s11019-021-10060-1 read 9 October 2026. doi.org/10.1007/s11019-021-10060-1
  8. DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, Hanekamp E, Dormer L, DiBiasi F, Bridges D, Baltzer L, Citrome L. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Annals of Internal Medicine. 2022;175(9):1298-1304. doi:10.7326/M22-1460 read 9 October 2026. doi.org/10.7326/M22-1460
  9. Vlahou A, Hallinan D, Apweiler R, Argiles A, Beige J, Benigni A, et al. Data sharing under the General Data Protection Regulation: time to harmonize law and research ethics? Hypertension. 2021;77:1029-1035. doi:10.1161/HYPERTENSIONAHA.120.16340 read 9 October 2026. doi.org/10.1161/HYPERTENSIONAHA.120.16340
  10. European Data Protection Board. Document on response to the request from the European Commission for clarifications on the consistent application of the GDPR, focusing on health research. EDPB. 2021. read 9 October 2026. ejprarediseases.org
  11. Crowhurst N, Bergin M, Wells J. Implications for nursing and healthcare research of the General Data Protection Regulation and retrospective reviews of patients' data. Nurse Researcher. 2019;27(1):45-49. doi:10.7748/nr.2019.e1639 read 9 October 2026. doi.org/10.7748/nr.2019.e1639
  12. European Data Protection Board. Opinion 3/2019 concerning the Questions and Answers on the interplay between the Clinical Trials Regulation and the GDPR. EDPB. 2019. read 9 October 2026. lw.com
  13. Richter G, Borzikowsky C, Lieb W, Schreiber S, Krawczak M, Buyx A. Patient views on research use of clinical data without consent: legal, but also acceptable? European Journal of Human Genetics. 2019;27:841-847. doi:10.1038/s41431-019-0340-6 read 9 October 2026. doi.org/10.1038/s41431-019-0340-6
  14. European Commission, Directorate-General for Health and Food Safety. Questions and Answers on the interplay between the Clinical Trials Regulation and the General Data Protection Regulation. European Commission. 2019. read 9 October 2026. research.uci.edu
  15. Rumbold JMM, Pierscionek BK. The effect of the General Data Protection Regulation on medical research. Journal of Medical Internet Research. 2017;19(2):e47. doi:10.2196/jmir.7108 read 9 October 2026. doi.org/10.2196/jmir.7108
  16. Chassang G. The impact of the EU general data protection regulation on scientific research. ecancermedicalscience. 2017;11:709. doi:10.3332/ecancer.2017.709 read 9 October 2026. doi.org/10.3332/ecancer.2017.709
  17. Mostert M, Bredenoord AL, Biesaart MC, van Delden JJ. Big data in medical research and EU data protection law: challenges to the consent or anonymise approach. European Journal of Human Genetics. 2016;24:956-960. doi:10.1038/ejhg.2015.239 read 9 October 2026. doi.org/10.1038/ejhg.2015.239
  18. Council for International Organizations of Medical Sciences. International Ethical Guidelines for Health-related Research Involving Humans, 4th edition. CIOMS. 2016. read 9 October 2026. equator-network.org
  19. European Union. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 (General Data Protection Regulation). Official Journal of the European Union. 2016. read 9 October 2026. frontiersin.org
  20. Kaye J, Whitley EA, Lund D, Morrison M, Teare H, Melham K. Dynamic consent: a patient interface for twenty-first century research networks. European Journal of Human Genetics. 2015;23:141-146. doi:10.1038/ejhg.2014.71 read 9 October 2026. doi.org/10.1038/ejhg.2014.71
  21. Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, Citrome L, Gurr JA, Mooney LA, Moore BJ, Pena T, Sanes-Miller CH, Veitch K, Woolley KL, Yarker YE. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Annals of Internal Medicine. 2015;163(6):461-464. doi:10.7326/M15-0288 read 9 October 2026. doi.org/10.7326/M15-0288
  22. Ploug T, Holm S. Meta consent: a flexible and autonomous way of obtaining informed consent for secondary research. BMJ. 2015;350:h2146. doi:10.1136/bmj.h2146 read 9 October 2026. doi.org/10.1136/bmj.h2146
  23. Casali PG; European Society for Medical Oncology. Risks of the new EU Data protection regulation: an ESMO position paper endorsed by the European oncology community. Annals of Oncology. 2014;25:1458-1461. doi:10.1093/annonc/mdu218 read 9 October 2026. doi.org/10.1093/annonc/mdu218
  24. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191-2194. doi:10.1001/jama.2013.281053 read 9 October 2026. doi.org/10.1001/jama.2013.281053
  25. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: consensus-based clinical case reporting guideline development. Journal of Medical Case Reports. 2013;7(1):223. doi:10.1186/1752-1947-7-223 read 9 October 2026. doi.org/10.1186/1752-1947-7-223
  26. Steinbrook R. Public registration of clinical trials. New England Journal of Medicine. 2004;351:315-317. doi:10.1056/NEJMp048191 read 9 October 2026. doi.org/10.1056/NEJMp048191
  27. Antes G, Chalmers I. Under-reporting of clinical trials is unethical. Lancet. 2003;361:978-979. read 9 October 2026. ismpp.org
  28. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research papers. BMJ. 1997;315:640-645. read 9 October 2026. ismpp.org
  29. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867-872. read 9 October 2026. ismpp.org
  30. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. US Department of Health, Education, and Welfare. 1978. read 9 October 2026. frontiersin.org

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 9). Regulatory Measures for Research Involving Human Participants: Ethical Declarations, Guidance, Legislation and Journal Policy. Pubrica. https://pubrica.com/academy/medical-writing/discuss-the-regulatory-measures-for-research-involving-human-participants/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Regulatory and ethics audit for a human-participants study

This audit should be completed before the study opens, not at manuscript stage, because three of the items below cannot be satisfied retrospectively. Names, references and dates should be entered rather than boxes merely ticked; the completed version is the basis from which the Methods section is written.

HUMAN PARTICIPANTS REGULATORY AUDIT
Study: ______________________   Coordinating institution: ______________________
Countries and sites: ______________________

A. WHICH INSTRUMENTS APPLY  (name them; do not write "applicable regulations")
   Ethical declaration relied on ...... Declaration of Helsinki, October 2024 revision
   International guidance ............. CIOMS 4th edition (2016) / other: ________
   National legislation .............. ______________________ (per country)
   Data protection law ............... ______________________ (per country)
   Journal policy .................... ICMJE Recommendations; COPE Core Practices

B. DEADLINES THAT CANNOT BE RECOVERED
   [ ] Ethics committee approval obtained BEFORE the study began
       Committee: ______________________  Ref: __________  Date: __________
   [ ] Trial registered in a public registry AT OR BEFORE first enrolment
       Registry and ID: ______________________  Registered: __________
       First participant enrolled: __________   (must be the later date)
   [ ] Protocol finalised and dated before recruitment, with version control

C. PROTOCOL CONTENT REQUIRED BY THE DECLARATION
   [ ] Funding sources stated
   [ ] Sponsors and institutional affiliations stated
   [ ] Conflicts of interest and incentives for participants stated
   [ ] Provision for treatment or compensation of participants harmed
   [ ] Plan for making results publicly available, including null results

D. CONSENT
   [ ] Written consent obtained before ANY study procedure
   [ ] Document covers purpose, procedures, risks, benefits, alternatives,
       funding, conflicts, voluntariness, withdrawal without penalty
   [ ] Comprehension checked, not just documented -- especially randomisation,
       research-versus-care, and the right to withdraw
   [ ] Route for participants lacking capacity, with assent where possible
   [ ] Re-consent triggers identified (protocol amendment, new safety data,
       long duration, transition of a minor to adulthood)

E. VULNERABILITY  (CIOMS analysis, not a category tick)
   Which specific features make these participants susceptible in THIS study?
   ______________________________________________________________
   Protections applied: ______________________________________________
   Post-trial access arrangements, where relevant: ____________________

F. DATA PROTECTION  (answers must come from the controller, in writing)
   Controller: ______________________  DPO consulted on: __________
   Legal basis stated by the institution: ______________________
   Special-category condition: ______________________
   National implementing law per site: ______________________
   [ ] Information sheet does not describe coded data as anonymous
   [ ] Information sheet does not promise deletion of data on withdrawal

G. METHODS-SECTION STATEMENT  (draft it now, from the above)
   [ ] Committee named with reference number, all sites accounted for
   [ ] "in accordance with the Declaration of Helsinki as revised in October 2024"
   [ ] Form of consent, who gave it, and the route for incapacity
   [ ] Registration ID with registration and first-enrolment dates
   [ ] Controller named; legal basis attributed to the institution, not the
       ethics committee

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica’s medical writing and regulatory teams prepare the ethics and governance sections of protocols and manuscripts so that each claim can be traced to the instrument that requires it. Pubrica distinguishes the requirements of the Declaration of Helsinki, CIOMS, the ICMJE and national law, identifies deadlines that cannot be met retrospectively, and drafts an ethics statement that a desk editor can verify readily. Pubrica does not provide legal opinions on data protection; it identifies the questions to put to the data protection officer and ethics committee and reports their answers accurately.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Pubrica reviews the protocol and identifies the ethics and regulatory requirements for which evidence is not yet documented.

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.